technology

IRRA Reports A Whopping 1045.49% Increase In Revenue From Its Line Of Electromedical Equipment

PT Itama Ranoraya Tbk (“IRRA”), a company specializing in high-tech medical equipment and supplies, has reported impressive growth for the first half of 2024. A standout achievement is the significant increase in sales for their Electromedical Equipment line, which reached Rp125.26 billion, showing a remarkable rise compared to the same period last year. This category includes top products like Radiotherapy (LINAC and CT Simulator), Extracorporeal Shock Wave Lithotripsy (ESWL), Laparoscopy, and Hemodialysis.

Not only in Electromedical Equipment, but the In Vitro Diagnostic product line also performed well, with sales hitting Rp176.08 billion. This marks a 34.7% increase from the previous year's figure of Rp130.71 billion.

Consistent with last year's performance, the In Vitro Diagnostic category remains a key revenue driver for the company, featuring flagship products such as reagents, rapid tests, and blood bags.

"From the start, we set a clear business strategy to accelerate organic growth, including through strategic partnerships and collaborations with principals and healthcare facilities. The surge in sales of our medical equipment reflects the market's trust in the quality and reliability of the products offered and distributed by the company," said Heru Firdausi Syarif, CEO of PT Itama Ranoraya Tbk.

Asset Growth and Partnerships for Long-Term Commitment

In its financial report, IRRA noted a significant increase in total assets, reaching Rp142.48 billion, bringing the total to Rp1.2 trillion in the first half of 2024. This rise highlights the company's financial strength, marked by growing assets. This success enables the company to maintain and expand its business operations more effectively.

Since the start of 2024, IRRA has successfully expanded its partnerships, including one with PT ZOLL Medical Indonesia. This collaboration focuses on providing medical equipment such as Defibrillator Monitors, Automated External Defibrillators (AEDs), Ventilators, and Cardiopulmonary Resuscitation (CPR) systems. This strategic move aligns with IRRA's commitment to its vision of being a dynamic, consistent, and sustainable healthcare company dedicated to delivering top-notch service and high-tech medical devices and pharmaceutical products. With this new partnership, IRRA is optimistic about enhancing healthcare services in the country through the supply and distribution of medical equipment.

Strong Second Quarter Close

Overall, IRRA wrapped up the second quarter of 2024 on a high note. The company reported revenues of Rp334.4 billion, up from Rp224.9 billion during the same period in 2023, marking a 48.7% year-on-year growth. The gross profit margin for this period reached 20.11%, showcasing effective cost management and strong profitability. IRRA also recorded a net profit of Rp8.87 billion for the current year.

“Our robust growth and strategic achievements reflect our commitment to continuously innovate and provide high-quality healthcare solutions to the community. Moving forward, we will keep our focus on maintaining this positive trend through product development and market expansion to offer innovative healthcare solutions for the Indonesian people while delivering sustainable value to our stakeholders,” said Viertin Maretson Lumban Tobing, CFO of PT Itama Ranoraya Tbk.

Tag: Electromedical Equipment IRRA LINAC And CT Simulator PT Itama Ranoraya Tbk